Granules India rises on US FDA nod for unit's ADHD treatment drug

Granules India

17/12/2024 06:20

** Shares of Granules India  GRAN.NS  turn positive, up 0.7%
at 588.40 rupees
    ** Pharma co's unit gets US FDA's approval for
Lisdexamfetamine Dimesylate chewable tablets, a generic for
Vyvanse chewable tablets
    ** Lisdexamfetamine dimesylate tablets are used to treat
attention deficit hyperactivity disorder and binge eating
disorder
    ** Stock was down ~0.5% before disclosure of US FDA approval
for unit's drug
    ** GRAN up ~45% YTD vs gains of 27% in 2023

 (Reporting by Vijay Malkar)
 ((VijayDattaram.Malkar@thomsonreuters.com;))